GNLX

Insider Trades

Name	Value	Action	Price	Current Price
Smalling RalphHead Of Regulatory $563192 shares SellJun 3, 2026 $2.93 --
Thomas JohnDirector $30k10k shares SellJun 1, 2026 $2.98 --
Cappello JosephChief Technical Officer $1.8k605 shares SellMay 11, 2026 $2.97 --
Smalling RalphHead Of Regulatory $804270 shares SellMay 11, 2026 $2.98 --
Yu YongChief Scientific Officer $1.8k605 shares SellMay 11, 2026 $2.97 --
Zindrick ThomasPresident And CEO $8.2k2.8k shares SellMay 11, 2026 $2.94 --

News

globenewswire.comGenelux Corporation Reports First Quarter Financial Results and Provides Business Updatesglobenewswire.comMay 7

Trade GNLX

About Genelux Corporation

Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.

CEO: Thomas D. Zindrick
IPO Date: Jan 26, 2023

Market Data

Open: $2.88
High: $2.98
Low: $2.83
Volume: 98.8K
Avg Volume: 189.3K
52W High: $8.54
52W Low: $2.29

Valuation

Market Cap: $112M
Enterprise Value: $105M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-26M
Revenue: $8.0k
Net Income: $-32M
Cash: $5.3M
Debt: $1.7M

Events

EarningsAug 6

EPS est. -0.2